Researchers in Canada analyzed more than 5,400 records of patients with glucagon-like peptide 1 receptor agonist prescriptions, such as Type 2 diabetes drugs Ozempic (semaglutide) and Saxenda (liraglutide), and weight loss medication Wegovy (semaglutide). Weight management drug Contrave (bupropion/naltrexone), which is not a GLP-1, was used as a comparison.
They found that the “use of GLP-1 agonists compared with bupropion-naltrexone was associated with increased risk of pancreatitis, bowel obstruction and gastroparesis, but not biliary disease.”
Gastroparesis is when the stomach paralyzes as food digestion slows. The first reports of this side effect appeared in July, and by August, a lawsuit was filed against Novo Nordisk over stomach paralysis claims.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
